App my Santa Maria
Alves, M., Conceição, I., & Luis, M. S. (1996). Neurophysiological evaluation of sexual dysfunction in familial amyloidotic polyneuropathy (FAP).Neuromuscular Disorders,6. doi:10.1016/0960-8966(96)88890-0
Alvir, J., Stewart, M., & Conceição, I. (2015). Latent Class Analysis to Classify Patients with Transthyretin Amyloidosis by Signs and Symptoms.Neurology and Therapy,4(1), 11-24. doi:10.1007/s40120-015-0028-y
Castro, J., Miranda, B., Castro, I., Carvalho, M. D., & Conceição, I. (2016). The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy.Clinical Neurophysiology,127(5), 2222-2227. doi:10.1016/j.clinph.2016.02.013
Coelho, T., Maia, L. F., Silva, A. M., Cruz, M. W., Plante-Bordeneuve, V., Lozeron, P., . . . Grogan, D. R. (2012). Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial.Neurology,79(8), 785-792. doi:10.1212/wnl.0b013e3182661eb1
Coelho, T., Maia, L. F., Silva, A. M., Cruz, M. W., Planté-Bordeneuve, V., Suhr, O. B., . . . Grogan, D. R. (2013). Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.Journal of Neurology,260(11), 2802-2814. doi:10.1007/s00415-013-7051-7
Conceicao, I. M., Miranda, L. C., Simoes, E., Gouveia, R. G., Evangelista, T. D., & Carvalho, M. A. (2005). Bone mineral density in familial amyloid polyneuropathy and in other neuromuscular disorders.European Journal of Neurology,12(6), 480-482. doi:10.1111/j.1468-1331.2005.01059.x
Conceição, I., Sales-Luis, M. L., Carvalho, M. D., Evangelista, T., Fernandes, R., Paunio, T., . . . Saraiva, M. J. (2003). Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: Clinical and neurophysiological studies.Muscle & Nerve,28(6), 715-721. doi:10.1002/mus.10474
Conceição, I., Carvalho, M., Alves, M., Luís, M.L. (1993). Familial amyloidotic polyneuropathy –Portuguese type– clinical and neurophysiologic course. Acta Med Port.,6(1):15-7.
Conceição, I., & Carvalho, M. D. (2006). Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal.Muscle & Nerve,35(1), 116-118. doi:10.1002/mus.20644
Conceição, I. M., Castro, J. F., Scotto, M., & Carvalho, M. D. (2008). Neurophysiological markers in familial amyloid polyneuropathy patients: Early changes.Clinical Neurophysiology,119(5), 1082-1087. doi:10.1016/j.clinph.2008.01.006
Conceição, I., Evangelista, T., Castro, J., Pereira, P., Silvestre, A., Coutinho, C. A., & Carvalho, M. D. (2010). Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation.Muscle & Nerve,42(5), 836-838. doi:10.1002/mus.21806
Conceição, I., Nzwalo, H., & Carvalho, M. D. (2012). Coexistence of transthyretin familial amyloid polyneuropathy and hereditary neuropathy with liability to pressure palsy.Clinical Neurology and Neurosurgery,114(10), 1355-1357. doi:10.1016/j.clineuro.2012.03.023
Conceição, I. (2012). Clinical features of TTR-FAP in Portugal.Amyloid,19(Sup1), 71-72. doi:10.3109/13506129.2012.673184
Conceição, I., Costa, J., Castro, J., & Carvalho, M. D. (2013). Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy.Muscle & Nerve,49(2), 181-186. doi:10.1002/mus.23901
Conceição, I., González-Duarte, A., Obici, L., Schmidt, H. H., Simoneau, D., Ong, M., & Amass, L. (2016). “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy.Journal of the Peripheral Nervous System,21(1), 5-9. doi:10.1111/jns.12153
Coutinho, C.A., Conceição, I., Almeida, A., Cantinho, G., Sargento, L., Vagueiro, M.C. (2004). Early detection of sympathetic myocardial denervation in patients with familial amyloid polyneuropathy type I. Rev Port Cardiol,23(2):201-11. English, Portuguese.
Coutinho, M. C., Cortez-Dias, N., Cantinho, G., Conceicao, I., Oliveira, A., Sa, A. B., . . . Diogo, A. N. (2013). Reduced Myocardial 123-Iodine Metaiodobenzylguanidine Uptake: A Prognostic Marker in Familial Amyloid Polyneuropathy.Circulation: Cardiovascular Imaging,6(5), 627-636. doi:10.1161/circimaging.112.000367
de Carvalho, M., Conceição, I., Bentes, C., Luís, M.L. (2002). Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M).Amyloid,9(2):126-33.
Ducla-Soares, J., Alves, M. M., Carvalho, M., Póvoa, P., Conceição, I., & Luis, M. L. (1994). Correlation between clinical, electromyographic and dysautonomic evolution of familial amyloidotic polyneuropathy of the Portuguese type.Acta Neurologica Scandinavica,90(4), 266-269. doi:10.1111/j.1600-0404.1994.tb02719.x
Ducla-Soares, J., Breitenfeld, L., Póvoa, P., Ferreira, M., Carvalho, M., Alves, M., . . . Palma-Carlos, A. D. (1991). Plasma catecholamines and postural hypotension in familial amyloidotic polyneuropathy of the Portuguese type.Clinical Autonomic Research,1(4), 271-274. doi:10.1007/bf01819831
Fonseca, C., Ceia, F., Carvalho, A., Nogueira, J.S., Morais, H., Conceição, I., Luís, M.L., Luís, A.S. (1997). The natural history of cardiac involvement in Portuguese-type familial amyloid polyneuropathy. Rev Port Cardiol.,16(1):101-5.
Inês, M., Coelho, T., Conceição, I., Duarte-Ramos, F., Carvalho, M., & Costa, J. (2015). Prevalence of Transthyretin Familial Amyloid Polyneuropathy In Portugal.Value in Health,18(7). doi:10.1016/j.jval.2015.09.2405
Inês, M., Coelho, T., Conceição, I., Duarte-Ramos, F., Carvalho, M., & Costa, J. (2015). Prevalence of Transthyretin Familial Amyloid Polyneuropathy In Portugal.Value in Health,18(7). doi:10.1016/j.jval.2015.09.2405
Inês, M., Coelho, T., Conceição, I., Duarte-Ramos, F., Carvalho, M., & Costa, J. (2015). Prevalence of Transthyretin Familial Amyloid Polyneuropathy In Portugal.Value in Health,18(7). doi:10.1016/j.jval.2015.09.2405
Inês, M., Coelho, T., Conceição, I., Ferreira, L., Carvalho, M., & Costa, J. (2015). Health-Related Quality of Life In Patients With Transthyretin Familial Amyloid Polyneuropathy.Value in Health,18(7). doi:10.1016/j.jval.2015.09.1997
Inês, M., Coelho, T., Conceição, I., Mourão, A., Carvalho, M., & Costa, J. (2015). Ambulatory Medicines Cost With Transthyretin Familial Amyloid Polyneuropathy In Portugal.Value in Health,18(7). doi:10.1016/j.jval.2015.09.2434
Sales-Luís, M.L., Conceição, I., de Carvalho, M. (2003). Clinical and therapeutic implications of presymptomatic gene testing for familial amyloidotic polyneuropathy (FAP).Amyloid,10 Suppl 1:26-31.
Sales-Luís, M.L., Galvão, M., Carvalho, M., Sousa, G., Alves, M.M., Serrão, R. (1991). Treatment of familial amyloidotic polyneuropathy (Portuguese type) by plasma exchange.Muscle Nerve,14(4):377-8
Soares, M. L., Coelho, T., Sousa, A., Batalov, S., Conceição, I., Sales-Luis, M. L., . . . Buxbaum, J. N. (2004). Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: Complexity in a single-gene disease.Human Molecular Genetics,14(4), 543-553. doi:10.1093/hmg/ddi051
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., . . . Adams, D. (2015). Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study.Orphanet Journal of Rare Diseases,10(1). doi:10.1186/s13023-015-0326-6
Teodoro, T., Viana, P., Abreu, D., Conceição, I., Peralta, R., & Ferreira, J. J. (2015). A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy.Parkinsonism & Related Disorders,21(12), 1465-1468. doi:10.1016/j.parkreldis.2015.10.012
Conceição I, Costa J, Castro J, de Carvalho M. Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle Nerve. 2014;49(2):181-186. doi:10.1002/mus.23901
Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-792. doi:10.1212/WNL.0b013e3182661eb1
Conceição I, González-Duarte A, Obici L, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5-9. doi:10.1111/jns.12153
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21. doi:10.1056/NEJMoa1716153
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22-31. doi:10.1056/NEJMoa1716793
Inês M, Coelho T, Conceição I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology. 2018;51(3-4):177-182. doi:10.1159/000490553
Conceição I, Coelho T, Rapezzi C, et al. Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression. Amyloid. 2019;26(3):103-111. doi:10.1080/13506129.2019.1627312
Conceição I. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. Clin Auton Res. 2019 Sep;29(Suppl 1):11-17. doi: 10.1007/s10286-019-00626-8. Epub 2019 Aug 9. PMID: 31399774; PMCID: PMC6763402.
Inês M, Coelho T, Conceição I, Landeiro F, de Carvalho M, Costa J. Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid. 2020;27(2):89-96. doi:10.1080/13506129.2019.1701429
Adams D, Polydefkis M, González-Duarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study [published correction appears in Lancet Neurol. 2021 Feb;20(2):e2]. Lancet Neurol. 2021;20(1):49-59. doi:10.1016/S1474-4422(20)30368-9
Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143-155. doi:10.1080/13506129.2022.2052838
